Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Benjamin L Maughan, MD

SWOG Cancer Research Network

Intervention

Atezolizumab(biological)

Enrollment

200 target

Eligibility

18 years · All sexes

Timeline

2023 – 2027

Study locations (30)

• Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Kaiser Permanente-Anaheim, Anaheim, California, United States
• Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
• Kaiser Permanente-Bellflower, Bellflower, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Epic Care-Dublin, Dublin, California, United States
• Epic Care Partners in Cancer Care, Emeryville, California, United States
• Kaiser Permanente-Fontana, Fontana, California, United States
• Kaiser Permanente South Bay, Harbor City, California, United States
• Kaiser Permanente-Irvine, Irvine, California, United States
• Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
• Kaiser Permanente West Los Angeles, Los Angeles, California, United States
• Contra Costa Regional Medical Center, Martinez, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Papillary renal cell carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05096390
  Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
  Centre Leon Berard
• ACTIVE NOT RECRUITINGPHASE3NCT05043090
  Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
  AstraZeneca

See all trials for Papillary renal cell carcinoma →